Clinical Trials

Gastrointestinal (Esophageal) Cancer

Trial Number—AT-101-CS-102

An open-label, single center, phase I/II trial to evaluate the safety and efficacy of the combination of chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer

Where is this study being conducted?

This study is currently being conducted at MD Anderson Cancer Center.

Who is conducting the trial?

This trial is being sponsored by Ascenta Therapeutics, Inc.

Who can participate?

Adults with histologically confirmed primary adenocarcinoma or squamous cell carcinoma of the esophagus or adenocarcinoma of the gastroesophageal junction.
Patients with distant metastases are not eligible.

What is AT-101?

AT-101 activates a pathway inside cancer cells resulting in the death of those cells. It is given by mouth in the form of pills.

What is chemoradiotherapy?

Chemoradiotherapy combines chemotherapy with radiotherapy.

What do I do if I am interested in participating in this clinical trial?

Contact your physician. Your physician will be able to advise you about participating.

Trial Identification Number

NCT00561197